Use of 2-phenylmorpholin-5-one derivatives

Details Use of 2-phenylmorpholin-5-one derivatives Use of 2-phenylmorpholin-5-one derivatives

1999-02-25

2001-07-24

Ramsuer, Robert W. (Department: 1613)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S128000, C544S131000, C544S174000

Reexamination Certificate

active

06265402

ABSTRACT:

TECHNICAL FIELD
The present invention relates to a novel 2-phenylmorpholin-5-one derivative having a type IV phosphodiesterase (PDE) inhibitory activity and a pharmaceutical composition containing the same.
BACKGROUND ART
Intracellular second messenger cAMP is involved in relaxation of airway smooth muscles and regulation of the functions of inflammatory cells. cAMP is broken down by phosphodiesterase (PDE) and becomes inactive 5′-AMP. It is considered that an increase in concentration of cAMP due to suppression of cAMP metabolism by PDE would give bronchodilating and anti-inflammatory actions and would exhibit a therapeutic effect on inflammatory diseases such as asthma [Eur. Respir. J., 7, 579 (1994)]. Up to now, PDE has been classified into five isozymes (i.e., types I to V PDE). Their distributions differ among tissues [Trends Pharm., Sci., 12, 19 (1991)]. This suggests a possibility that selective inhibitors of PDE isozymes would result in tissue specific increase of intracellular cAMP concentration.
It is reported that a selective inhibitor of type IV PDE isozyme suppresses inflammatory cells functions [Thorax, 46, 512 (1991)] and is useful for inflammatory diseases such as asthma [J. Pharmacol. Exp. Ther., 266, 306 (1993)] and dermatitis [Br. J. Pharmacol., 112, 332 (1994)] and autoimmune diseases such as multiple sclerosis [Nature Medicine, 1, 244 (1994)] and rheumatoid arthritis [Clin. Exp. Immunol., 100, 126 (1995)].
In addition, it is thought that cardiovascular side effect caused by non-selective PDE inhibitors such as theophylline could be reduced by using selective type IV PDE inhibitor. Rolipram having the following formula (Japanese Unexamined Patent Publication (Kokai) No. 50-157360) is known as a compound having a specific inhibitory activity against type IV PDE.
Although other compounds having a specific inhibitory activity against type IV PDE are known (Japanese Unexamined Patent Publication (Kokai) No. 62-281864, U.S. Pat. No. 5,128,358, WO 94/10118, WO 94/12461, Japanese Unexamined Patent Publication (Kokai) No. 5-117239, Japanese Unexamined Patent Publication (Kokai) No. 7-101861, WO 95/03794, WO 95/08534, etc.), they have not been clinically applied up to now. Thus, more useful compounds are desired to be. Further, Japanese Unexamined Patent Publication (Kokai) No. 64-6262 discloses a compound having the following formula (II)
wherein W is optionally substituted phenyl group, and RI is secondary or tertiary C
3
to C
6
alkyl group as a synthetic intermediate of a compound having the activity of increasing the weight gain of livestock and/or improving feed utilization efficiency. Japanese Unexamined Patent Publication (Kokai) No. 59-116288 describes a compound having the following formula (III):
wherein R and R
1
may be the same or different and represent a hydrogen atom, a C
1
to C
18
alkyl group or a phenyl group, which groups may be substituted, R
2
represents a hydrogen atom, a C
1
to C
6
alkyl group, a C
8
to C
18
arylalkyl group which may be substituted with any number up to five of fluorine atoms, chlorine atoms, or bromine atoms, etc.
as a synthetic intermediate of a compound having a lipoxygenase inhibitory activity. U.S. Pat. No. 3,308,121 describes a compound having the following formula (IV):
wherein R
3
represents a hydrogen atom or a lower hydroxyalkyl group, R
4
represents a hydrogen atom, a lower alkyl group, an acyl group, etc., R
5
and R
6
independently represent a hydrogen atom, a lower alkyl group or an aryl group, Ar represents a phenyl group and a substituted phenyl group substituted with a halogen atom, a hydroxy group, a lower alkoxy group, a benzyloxy or a halogenated lower alkyl group, and X indicates an oxygen atom or a sulfur atom,
as a muscle relaxant and tranquillizer.
DISCLOSURE OF THE INVENTION
An object of the present invention is to develop a novel compound having a type IV PDE inhibitory activity.
In accordance with the present invention, there are provided a 2-phenylmorpholin-5-one derivative having the formula (I):
wherein R
1
represents a substituted or unsubstituted C
1
to Ca alkyl group; a substituted or unsubstituted C
3
to C
7
cycloalkyl group; or indanyl group, R
2
represents a C
1
to C
4
alkyl group, R
3
represents a hydrogen atom; a substituted or unsubstituted C
1
to C
5
alkyl group; a substituted or unsubstituted C
3
to C
7
cycloalkyl group; a substituted or unsubstituted aryl group which may include at least one hetero atom selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom; or an acyl group, R
4
represents a hydrogen atom; a substituted or unsubstituted C
1
to C
6
alkyl group; or a substituted or unsubstituted aryl group which may include at least one hetero atom selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, R
5
and R
6
independently represents a hydrogen atom; a substituted or unsubstituted C
1
to C
5
alkyl group; a substituted or unsubstituted C
3
to C
7
cycloalkyl group; or a substituted or unsubstituted aryl group which may include at least one hetero atom selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom,
an optical isomer thereof, or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof; and
a pharmaceutical composition comprising, as an essential ingredient, these compounds.
BEST MODE FOR CARRYING OUT THE INVENTION
The present invention will be explained in detail below.
The present inventors conducted a search for a novel compound having a type IV PDE inhibitory activity and, as a result, found that the above 2-phenylmorpholin-5-one derivative had a strong type IV PDE inhibitory activity and had a bronchodilator and antiinflammatory effects, whereby the present invention was completed.
As the C
1
to C
8
linear or branched alkyl group of R
1
in the compound having the above formula (I), methyl, ethyl, propyl, isopropyl, n-butyl, 2-methylpropyl, sec-butyl, t-butyl, n-pentyl, 1,1-dimethylpropyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2-ethylbutyl, n-heptyl, n-octyl, etc. may be mentioned. These groups may be substituted with a halogen atom; a hydroxy group; a nitro group; a cyano group; an amino group; a carboxyl group; an aryl group such as phenyl, tolyl, naphthyl, pyridyl, thiazolyl, thienyl, furyl, quinolyl, etc.; a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.; a haloalkyl group; a carbamoyl group; an alkoxy group; an alkylcarbonyl group; etc. Specifically, as the substituents for the substituted C
1
to C
8
alkyl group, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 1-methylcyclopropylmethyl, 1-phenylcyclopropylmethyl, 1-methylcyclobutylmethyl, 1-methylcyclopentylmethyl, 1-methylcyclohexylmethyl, 2-indanylmethyl, benzyl, phenethyl, 4-fluorophenethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 2-(1-naphthyl)ethyl, 2-(2-pyridyl)ethyl, 2-(benzyloxy)ethyl, 2-(phenethyloxy)ethyl, 2-(methoxy)ethyl, 3-(methoxy)propyl, 4-(methoxy)butyl, 2-(cyclopropylmethoxy)ethyl, 2-(cyclopentyloxy)ethyl, 2-(2-indanyl)ethyl, etc. may be mentioned.
As the C
3
to C
7
cycloalkyl group of R
1
, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. may be mentioned. These groups may be substituted with a halogen atom; an alkyl group; a hydroxy group; a nitro group; a cyano group; an amino group; a carboxyl group; an aryl group such as phenyl, tolyl, naphthyl, pyridyl, thiazolyl, thienyl, furyl, quinolyl, etc.; a cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc.; a haloalkyl group; a carbamoyl group; an alkoxyl group; an alkylcarbonyl group; etc. Specifically, as the substituents for the substituted C
3
to C
7
cycloalkyl group, 4-phenylcyclohexyl, 1-methylcyclopentyl, etc. may be mentioned. Further, as the substituent R
1
, an indanyl group may be mentioned.
As the substituent R
1
, preferably, a C
1
to C
6
alkyl group; a substituted C
1
to C
5
alkyl

Affiliated with

Also associated with

Rating

Use of 2-phenylmorpholin-5-one derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of 2-phenylmorpholin-5-one derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2-phenylmorpholin-5-one derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2516526